Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

21. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

2012 FDA - Drug Approval Package

22. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | BMJ Evidence-Based Medicine We (...) of institutional accounts Username * Password * your user name or password? You are here The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity

2012 Evidence-Based Medicine

23. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. (Abstract)

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet (...) and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors.In this 56-week phase 3 trial, we randomly assigned overweight or obese adults (aged 18-70 years), with a body-mass index of 27-45 kg/m(2) and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obesity) to placebo, once-daily phentermine 7·5 mg plus topiramate 46·0 mg, or once-daily phentermine 15·0 mg plus topiramate

2011 Lancet Controlled trial quality: predicted high

24. Clinical Assessment of Topiramate Therapy in Patients With Migrainous Vertigo (Abstract)

Clinical Assessment of Topiramate Therapy in Patients With Migrainous Vertigo To assess the efficacy of topiramate in reducing both the frequency and the severity of vertigo and headache attacks in patients with migrainous vertigo and to compare 50 and 100 mg/day doses of the drug.Thirty patients diagnosed as definite migrainous vertigo were recruited in the study. Vertigo and headache frequency was determined as the monthly number of attacks whereas severity was determined by visual analog (...) scales measured in millimeters from 0 to 100. Patients were randomized to either 50 or 100 mg/day topiramate for 6 months. Vertigo and headache frequency and severity were evaluated at the end of the study period.Number of mothly vertigo attacks decreased significantly in the overall group after treatment (median from 5.5 to 1; P < .01). The same was true for monthly headache attacks (median from 4 to 1; P < .01). A statically significant improvement in vertigo severity was noted (median from 80

2010 EvidenceUpdates Controlled trial quality: uncertain

25. Ocular side effects of Topiramate: Frequently asked questions

Ocular side effects of Topiramate: Frequently asked questions The Royal College of Ophthalmologists Ocular side effects of Topiramate- Frequently asked questions 1. What is Topiramate and when is it indicated clinically? Topiramate is a sulfamate-substituted monosaccharide derived from D-fructose. Its is used mainly as an antiepileptic drug both as mono-therapy and as an adjunct in the control of partial and primary generalised epilepsy in adults and children above the age of two 1-3 (...) . Effectiveness in migraine prophylaxis, trigeminal neuralgia, bipolar disorders, depression and eating disorders has also been reported 4-8 . Recently it is been used to treat idiopathic intracranial hypertension 9, 10 . In an open label study it has been show to be as effective as acetazolamide in the treatment of intracranial hypertension 11 . 2. How does topiramate work? It, acts predominantly by inactivating the sodium and or calcium gate channels, hyperpolarising K + currents, inhibition of kainate

2010 Royal College of Ophthalmologists

26. Review of the Ocular side effects of Topiramate

Review of the Ocular side effects of Topiramate RCOphth reference: 2010/PROF/122 Original document 2006 Reviewed October 2010 1 A Review of the Ocular side effects of Topiramate Author: Patrick Watts This manuscript was reviewed by Paediatric Ophthalmology Subcommittee, Royal College of Ophthalmologists Address for Correspondence: Mr Patrick Watts Department of Ophthalmology University Hospital of Wales Cardiff CF14 4XW Telephone: (+44) 2920748583 Fax: (+44) 2920748240 Keywords: Topiramate (...) , Glaucoma RCOphth reference: 2010/PROF/122 Original document 2006 Reviewed October 2010 2 Abstract Acute angle closure glaucoma and visual blurring due to induced myopia have been reported with the use of the antiepileptic drug topiramate. Various hypotheses have been put forward to explain the mechanism of the aforementioned ocular side effects. These presumed ocular side effects of topiramate have included patients treated with other drugs such as serotonin reuptake inhibitors which are also reported

2010 Royal College of Ophthalmologists

27. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) , oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text Aetiology New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Statistics from Altmetric.com Question Question Is new use of anticonvulsants associated with an increased risk of suicidal acts or violent death? People 297 620 people aged over 15 years of age who began taking

2010 Evidence-Based Mental Health

28. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Full Text available with Trip Pro

Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Verdian L, Yi Y Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of the addition of rufinamide compared with topiramate or lamotrigine for children with Lennox-Gastaut Syndrome that was uncontrolled by up to three traditional

2010 NHS Economic Evaluation Database.

29. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age (Abstract)

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents.Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly (...) to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in monthly migraine attacks, with the use of the 48-hour rule, from the prospective baseline period to the last 12 weeks of the double-blind phase. The 48-hour rule defined a single migraine episode as all recurrences of migraine symptoms within 48 hours after onset. Several secondary efficacy measures were evaluated, including the reduction from baseline

2009 EvidenceUpdates Controlled trial quality: predicted high

30. Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

31. Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder

Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder Article Text Therapeutics Topiramate improves

2007 Evidence-Based Mental Health

32. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term (...) outcomes, quality of life, and health economic outcomes.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol

2007 Lancet Controlled trial quality: predicted high

33. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Valproate is widely accepted as a drug of first choice for patients with generalised onset seizures, and its broad spectrum of efficacy means it is recommended for patients with seizures that are difficult to classify. Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare (...) the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm B of the study recruited 716 patients for whom valproate was considered to be standard treatment. Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. Primary outcomes

2007 Lancet Controlled trial quality: predicted high

34. Topiramate for treating alcohol dependence: a randomized controlled trial. Full Text available with Trip Pro

Topiramate for treating alcohol dependence: a randomized controlled trial. Hypothetically, topiramate can improve drinking outcomes among alcohol-dependent individuals by reducing alcohol's reinforcing effects through facilitation of gamma-aminobutyric acid function and inhibition of glutaminergic pathways in the corticomesolimbic system.To determine if topiramate is a safe and efficacious treatment for alcohol dependence.Double-blind, randomized, placebo-controlled, 14-week trial of 371 men (...) and women aged 18 to 65 years diagnosed with alcohol dependence, conducted between January 27, 2004, and August 4, 2006, at 17 US sites.Up to 300 mg/d of topiramate (n = 183) or placebo (n = 188), along with a weekly compliance enhancement intervention.Primary efficacy variable was self-reported percentage of heavy drinking days. Secondary outcomes included other self-reported drinking measures (percentage of days abstinent and drinks per drinking day) along with the laboratory measure of alcohol

2007 JAMA Controlled trial quality: predicted high

35. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

36. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

37. Topiramate for acute affective episodes in bipolar disorder. (Abstract)

Topiramate for acute affective episodes in bipolar disorder. Bipolar disorder is a common recurrent illness with high levels of chronicity. Treatment resistance persists despite the use of established medications, such as lithium and valproate. New medications are required for the treatment of refractory cases. Retrospective and open-label trials have suggested that the anticonvulsant topiramate may be efficacious in bipolar disorder. There is a need to clarify the evidence available (...) in the form of randomised controlled trials for its use in bipolar disorder.To review the evidence for the efficacy and acceptability of topiramate in the treatment of acute mood episodes in bipolar disorder.The Cochrane Collaboration Depression, Anxiety and Neurosis (CCDAN) group search strategy was used. The following databases were searched:The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), September 2003;The Cochrane Controlled Clinical Trials Register

2006 Cochrane

38. Cost effectiveness of topiramate in the prevention of migraines in the United States: an update

Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Cost effectiveness of topiramate in the prevention of migraines in the United States: an update Brown J S, Rupnow M F, Neumann P, Friedman M, Menzin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of topiramate (100 mg/day) in the prevention of migraine. This intervention was compared with no preventive treatment. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised working adults who were appropriate candidates for migraine

2006 NHS Economic Evaluation Database.

39. Cost-effectiveness of migraine prevention: the case of topiramate in the UK Full Text available with Trip Pro

Cost-effectiveness of migraine prevention: the case of topiramate in the UK Cost-effectiveness of migraine prevention: the case of topiramate in the UK Cost-effectiveness of migraine prevention: the case of topiramate in the UK Brown J S, Papadopoulos G, Neumann P J, Price M, Friedman M, Menzin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study assessed the use of topiramate (TPM, 100 mg/day), a neuromodulatory compound with stabilising properties, as a migraine preventive therapy. This was compared with no preventive therapy. Type of intervention Primary care. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population for the model comprised adults

2006 NHS Economic Evaluation Database.

40. Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol depe Full Text available with Trip Pro

Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol depe Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol dependence | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral topiramate was effective as an adjunct to standardised medication compliance management in alcohol dependence Article Text Therapeutics Oral topiramate

2005 Evidence-Based Medicine